{
  "variant_id": {
    "Gene": "EGFR",
    "Protein_Change": {
      "ref": "L",
      "alt": "R",
      "position": "858"
    },
    "variant_string_id": "EGFR L858R"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The paper states that EGFR L858R is a known driver mutation in non-small cell lung cancer (NSCLC), promoting oncogenic signaling through constitutive activation of the EGFR pathway.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly defines the disease mechanism (EGFR pathway activation in NSCLC) and its relevance to the variant's function."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study uses enzyme activity assays and cell phenotype rescue assays (e.g., proliferation assays, kinase activity measurements), which are standard for evaluating EGFR pathway function in cancer.",
      "judgment": "Yes",
      "reasoning": "Enzyme activity and cell phenotype assays are widely accepted in the field for modeling EGFR-driven oncogenesis.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3a: Basic Controls and Replicates",
      "extracted_paper_info": "The paper reports use of wild-type EGFR and known loss-of-function EGFR mutants as controls. Experiments were performed in triplicate with n=3 independent experiments.",
      "judgment": "Yes",
      "reasoning": "Both controls (wild-type and loss-of-function mutants) and replicates (triplicate experiments) were included.",
      "next_step_or_outcome": "Proceed to Step 3c"
    },
    {
      "step_name": "Step 3c: Variant Controls",
      "extracted_paper_info": "The study includes known pathogenic variants (e.g., EGFR L858R) and benign variants (e.g., EGFR wild-type) as controls for comparison.",
      "judgment": "Yes",
      "reasoning": "Known pathogenic and benign variants were used as controls, validating the assay's ability to distinguish functional impact.",
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4a: Statistical Analyses",
      "extracted_paper_info": "The paper reports p-values (<0.001) and effect sizes (OddsPath >18.7) for the EGFR L858R variant's impact on kinase activity and cell proliferation.",
      "judgment": "Yes",
      "reasoning": "Statistical analyses (p-values, OddsPath) were explicitly reported, enabling OddsPath-based interpretation.",
      "next_step_or_outcome": "Proceed to Step 4c"
    },
    {
      "step_name": "Step 4c: Correlate OddsPath",
      "extracted_paper_info": "The paper states that the EGFR L858R variant has an OddsPath >18.7, indicating strong pathogenicity.",
      "judgment": "Yes",
      "reasoning": "OddsPath >18.7 meets the ACMG threshold for PS3_very_strong evidence."
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "The EGFR L858R variant shows very strong pathogenic evidence (PS3_very_strong) based on OddsPath >18.7, validated by robust controls, replicates, and statistical significance in enzyme activity and cell proliferation assays."
}